Bristol-Myers Squibb Reports First Randomized Study Evaluating Opdivo+Yervoy Regimen Shows Superior Efficacy Related to Yervoy Alone - Bristol-Myers Squibb (NYSE:BMY)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Bristol-Myers Squibb Company (NYSE: BMY) today announced positive results froma Phase II trial (CheckMate -069), evaluating the Opdivo (nivolumab)+Yervoy(ipilimumab) regimen versus Yervoy alone in patients with previously untreatedadvanced melanoma. Patients with BRAF wild-type mutation status treated withthe Opdivo+Yervoy regimen experienced a higher objective response rate (ORR)of 61% (n=44/72) – the primary study endpoint – compared to 11% (n=4/37) forpatients administered Yervoy monotherapy (P

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!